MTSL Issue 869

 Comments Off on MTSL Issue 869
Jan 212018
 
MTSL Issue 869

MTSL Issue 869 (dated 01/18/18) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ESPR #INCY #MDGL #MDCO #NKTR #PCRX #SGMO #ZIOP

MTSL Issue 868

 Comments Off on MTSL Issue 868
Jan 072018
 
MTSL Issue 868

MTSL Issue 868 (dated 01/04/18) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #FPRX #PCRX #SGMO

MTSL Issue 864

 Comments Off on MTSL Issue 864
Nov 122017
 
MTSL Issue 864

MTSL Issue 864 (dated 11/09/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #ESPR #FPRX #INCY #IONS #MDCO #MYOV #NKTR #PCRX #SGMO #ZIOP

TAU – The Next Target For Neurology Focus On IONS and SGMO

 Comments Off on TAU – The Next Target For Neurology Focus On IONS and SGMO
Oct 302017
 
TAU – The Next Target For Neurology Focus On IONS and SGMO

ESPR continues to execute at a Big Pharma/Bio level with a small, emerging Company focus. After the successful trial, the Company raised $150 million at $49 per share. Reiterate our BUY under 55 rating with a 70 TARGET PRICE.

MTSL Issue 863

 Comments Off on MTSL Issue 863
Oct 292017
 
MTSL Issue 863

MTSL Issue 863 (dated 10/26/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ESPR #INCY #XON #MDGL #MDCO

Esperion: Grand Slam in Cholesterol Reduction

 Comments Off on Esperion: Grand Slam in Cholesterol Reduction
Sep 072017
 
Esperion: Grand Slam in Cholesterol Reduction

Non-alcoholic steatohepatitis, or NASH, is one of the largest disease opportunities we have ever seen, explains John McCamant, editor of The Medical technology Stock Letter.

MTSL Issue 858

 Comments Off on MTSL Issue 858
Aug 202017
 
MTSL Issue 858

MTSL Issue 858 (dated 8/17/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #ANTH #BMRN #ESPR #FPRX #INCY #IONS #MDCO #MDGL #NKTR #PCRX #SGMO #XON #ZIOP

MTSL Issue 857

 Comments Off on MTSL Issue 857
Jul 302017
 
MTSL Issue 857

MTSL Issue 857 (dated 7/27/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ESPR #INCY #IONS #MDCO #NKTR #NVAX #PCRX

MTSL Issue 855

 Comments Off on MTSL Issue 855
Jul 022017
 
MTSL Issue 855

MTSL Issue 855 (dated 6/29/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ESPR #SGMO #ZIOP

MTSL Issue 854

 Comments Off on MTSL Issue 854
Jun 182017
 
MTSL Issue 854

MTSL Issue 854 (dated 6/15/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #INCY #XON #NKTR #FPRX #ZIOP

MTSL Issue 851

 Comments Off on MTSL Issue 851
May 072017
 
MTSL Issue 851

MTSL Issue 851 (dated 5/04/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #BMRN #CELG #ESPR #FPRX #INCY #IONS #MDCO #PCRX #SGMO #ZIOP

MTSL Issue 849

 Comments Off on MTSL Issue 849
Apr 022017
 
MTSL Issue 849

MTSL Issue 849 (dated 3/30/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ANTH #ESPR #IONS #NKTR #SGMO #ZIOP

Esperion (ESPR) 02-20-17

 Comments Off on Esperion (ESPR) 02-20-17
Mar 232017
 
Esperion (ESPR)  02-20-17

BIOINVEST BREAKING NEWS – Esperion Therapeutics (ESPR) – FDA Shows Esperion “The Way to Approval” – Raising BUY to 40 and TARGET PRICE to 60

This morning, ESPR announced that the FDA has confirmed that the bempedoic acid Phase III development program is adequate to support an approval prior to their CVOT results, lifting one of the largest overhangs on the stock, and creating a clear path to an earlier-than-expected approval.